Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c

Table 1 Baseline characteristics of all patients treated with direct-acting antivirals n (%)

	All patients (n = 1068)	SVR12 not achieved (n = 138)	SVR12 achieved (n = 930)	P-value
Age (mean ± SE, yr)	61.8 ± 0.2	60.7 ± 0.5	62.0 ± 0.2	0.02
Sex
Male	97.5 (1041)	12.8 (133)	87.2 (908)	0.78
Female	2.5 (27)	18.500 (5)	81.50 (22)
Race/ethnicity
White	37.5 (400)	11.00 (44)	89.0 (356)	0.14
African American	37.5 (401)	14.70 (59)	85.3 (342)
Hispanic	15.1 (161)	16.80 (27)	83.2 (134)
Asian	0.70 (7)	14.30 (1)	85.700 (6)
Other	9.3 (99)	7.10 (7)	92.90 (92)
Fib4 < 3.25	64.6 (690)	9.1 (63)	90.9 (627)	< 0.01
Fib4 ≥ 3.25	35.4 (378)	19.80 (75)	80.2 (303)
Treatment naïve	79.5 (849)	16.4 (102)	83.6 (747)	0.09
Treatment experienced	20.5 (219)	16.40 (36)	83.6 (183)
HCV genotype
HCV genotype 1a	58.0 (619)	12.10 (75)	87.9 (544)	< 0.01
HCV genotype 1b	25.9 (277)	10.10 (28)	89.9 (249)
HCV genotype 2	7.9 (84)	21.40 (18)	78.60 (66)
HCV genotype 3	6.9 (74)	23.00 (17)	77.00 (57)
HCV genotype 4	1.2 (13)	0.00 (0)	100.0 (13)
HCV genotype 6	0.10 (1)	0.00 (0)	100.0 (1)
Treatment
PrOD	4.5 (48)	8.30 (4)	91.70 (44)	0.01
PrOD/RBV	17.6 (188)	14.40 (27)	85.6 (161)
Sofosbuvir/Ledipasvir	34.4 (367)	6.3 (23)	93.7 (344)
Sofosbuvir/Ledipasvir/RBV	13.4 (143)	13.30 (19)	86.7 (124)
Sofosbuvir/RBV	9.8 (105)	23.80 (25)	76.20 (80)
Sofosbuvir/Simeprevir	17.5 (187)	19.80 (37)	80.2 (150)
Other regimens	2.9 (30)	10.0 (3)	90.00 (27)
No HIV	96.7 (1033)	13.1 (135)	86.9 (898)	0.44
HIV	3.3 (35)	8.60 (3)	91.40 (32)
Duration of treatment
8 wk	19.9 (213)	6.6 (14)	93.4 (199)	< 0.01
12 wk	73.1 (781)	13.4 (105)	86.6 (676)
16 wk	2.8 (30)	40.00 (12)	60.00 (18)
24 wk	4.1 (44)	15.90 (7)	84.10 (37)
BMI < 30	66.5 (710)	12.50 (89)	87.5 (621)	0.60
BMI > 30	33.5 (358)	13.70 (49)	86.3 (309)
No HTN	43.7 (467)	13.30 (62)	86.7 (405)	0.76
HTN	56.3 (601)	12.60 (76)	87.5 (525)
No T2DM	85.6 (914)	12.4 (113)	87.6 (801)	0.15
T2DM	14.4 (154)	16.20 (25)	83.8 (129)
No HLD	58.1 (620)	14.50 (90)	85.5 (530)	0.70
HLD	41.9 (448)	10.70 (48)	89.3 (400)
No metabolic syndrome	87.1 (930)	13.0 (121)	87.0 (809)	0.84
Metabolic syndrome	12.9 (138)	12.30 (17)	87.7 (121)

PrODL: Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir; Fib4: Fibrosis 4 score; RBV: Ribavirin; BMI: Body mass index; HTN: Hypertension; T2DM: Type 2 diabetes mellitus; HLD: Hyperlipidemia; SVR: Sustained virologic response; HCV: Hepatitis C virus.